FDA Delay: Catastrophic Equine Product Contamination Case Released 8 Months After Horse Deaths Begin

By Mollie Morrissette

What was marketed to veterinarians across the United States as a sterile, medical-grade hyaluronate sodium solution turned out to be a lethal vector for drug-resistant mold. Nearly 100 horses across the country suffered severe, debilitating infections—with at least 20 humanely euthanized—after receiving contaminated vials of Neogen Vet HYCOAT.

Behind this outbreak lies a dual failure: a distributor that evaded drug safety regulations by marketing injectable packaging as a “topical device,” and a contract manufacturer operating out of a grime-caked warehouse plagued by ceiling leaks, gap-ridden doors, and pest ingress. Even more damning is the timeline: federal inspectors documented these horrific conditions in February 2026, yet the Food and Drug Administration (FDA) waited until September 23, 2026—seven months later—to issue formal Warning Letters alerting the public.

To understand the severity of this disaster, one must look at the physiological destruction wrought by Purpureocillium lilacinum—a spore-forming fungal mold isolated directly from HYCOAT vials by FDA laboratories.

Medical Pathology of Fungal Septic Arthritis: What Happened to the Horses

While corporate executives and government officials passed paperwork back and forth for eight months, horses given these injections endured agonizing physical destruction:

The FDA formally cited Neogen for misbranding and adulteration under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for distributing a product labeled as “sterile” that contained five distinct strains of live mold (Purpureocillium lilacinum, Paraisaria heteropoda, Gongronella lacrispora, Purpureocillium sodanum, and Isaria takamizusanensis).

To understand the severity of this disaster, one must look at the physiological destruction wrought by Purpureocillium lilacinum—a spore-forming fungal mold isolated directly from HYCOAT vials by FDA laboratories.

• Eaten Away From the Inside Out: A horse’s joint is a sealed, fluid-filled space. When mold spores were injected into the joint, it became an ideal breeding ground. The mold multiplied rapidly, eating away at the smooth joint lining and permanently destroying the cushioning cartilage right down to the bone. Because cartilage cannot regenerate, the joint damage was permanent.

• Immune to Treatment: Normal joint infections are caused by bacteria, which veterinarians can fight with standard antibiotics. But this specific mold is virtually immune to standard antifungal medicines. Even when vets repeatedly flushed out the joints with surgery and flooded the horses with drugs, the mold kept growing, leaving veterinarians helpless as the horses suffered in extreme pain.

• The Fatal Chain Reaction (Supporting-Limb Laminitis): When a horse’s infected leg became too painful to bear weight on, it had no choice but to shift all 1,000+ pounds of its body weight onto its opposite, healthy leg. Holding that massive weight continuously crushes the tiny blood vessels inside the healthy hoof. This causes an excruciating, secondary condition called supporting-limb laminitis—effectively destroying the good leg, too.

Facing melted joint cartilage, ruined hooves, and unbearable agony that no medicine could stop, veterinarians and grieving owners were left with only one humane choice: putting their horses down.

Clinical Outlook Summary

Outcome Category	Estimated Incidence	Pathological Basis
Humane Euthanasia / Fatality	≥20% of reported cases	Uncontrolled fungal necrosis, drug-resistant infection, or secondary laminitis of the supporting limb (Purdue Veterinary Medicine).
Permanent Osteoarthritis & Lameness	70% – 80% of survivors	Irreversible cartilage destruction and bone erosion causing permanent loss of athletic function (Purdue Veterinary Medicine).
Full Soundness Recovery	<10% – 15%	Extremely rare once deep fungal hyphae establish within synovial joint structures (Purdue Veterinary Medicine).

---

The 8-Month Regulatory Delay & Inaction

The primary regulatory failure lies in the eight-month gap between the discovery of fungal contamination and the FDA’s formal public enforcement action.

Late 2025: Initial Outbreak Reports & Deceptive Packaging
Equine veterinarians began filing adverse event reports directly with the FDA Center for Veterinary Medicine (CVM) after horses developed agonizing joint infections following administration of HYCOAT. Veterinarians were unaware of the risk because the product was packaged in glass vials with rubber septum caps, which led practitioners to administer it as an injectable sodium hyaluronate joint treatment rather than as a topical wound dressing.

January 28, 2026: Voluntary Recall Initiated
Neogen initiated a voluntary recall of all unexpired 2-mL and 10-mL vials. The FDA posted this notice on January 29, 2026, but left it unclassified without detailing the mortality rate or specific pathogens.

February 25, 2026: The Inspection & Form FDA 483 Violations
FDA inspectors audited contract manufacturer Sciarra Aeromed, Inc., completing the audit on February 25, 2026, and issuing a Form FDA 483. FDA investigators found the manufacturer operating out of a filthy, grime-caked warehouse plagued by ceiling leaks, gap-ridden doors, and pest ingress. Sciarra Aeromed manufactured products labeled as “sterile” in a cleanroom setup inside a warehouse that lacked basic sporicidal cleaning agents, failed to monitor room air pressure differential or airborne particle levels, and exposed open glass vials and rubber stoppers to unsterilized environmental air.

Below are the official, verbatim captions provided by the FDA directly beneath the photographic exhibits in Warning Letter MARCS-CMS 728248:

Description: Exit door of the warehouse where the cleanroom is located, with large gaps allowing pest ingress. The area contains numerous black and brown residues of unknown identity.

Description: Ceiling leaks and brown staining appear to be water damage next to an unclassified weigh booth of the cleanroom suite.

Description: Close-up of ceiling near cleanroom.

Following the February 2026 audit, Sciarra Aeromed submitted a written response addressing the Form FDA 483 observations. However, when FDA scientists evaluated the company’s submissions, they determined the response failed to provide evidence across six critical operational areas:

1. Failed to include media fill data simulating worst-case production.

2. Failed to provide evidence of adequate personnel monitoring in ISO 5 and ISO 7 zones.

3. Failed to provide proof of the use of a sporicidal cleaning agent or of overall environmental disinfection.

4. Failed to provide differential pressure gauge and temperature monitoring records.

5. Failed to provide viable particulate-sampling data (e.g., settling plates) during production.

6. Failed to provide dynamic smoke-airflow study data for the ISO 5 laminar-flow hoods.

Despite knowing by spring 2026 that Sciarra Aeromed’s response provided zero valid scientific proof that the plant could manufacture a sterile product, the FDA took seven months—until September 23, 2026—to issue formal Warning Letters.

September 23–29, 2026: Formal Warning Letters Issued
Despite uncovering gross manufacturing failures during its mid-February 2026 inspection and issuing a Form FDA 483 with the standard 15-working-day corrective window, the Food and Drug Administration (FDA) allowed seven months to pass before taking public enforcement action. It was not until September 23, 2026—after seven months of administrative silence—that the agency finally issued formal Warning Letters to Neogen Corporation and Sciarra Aeromed, Inc., alerting the public to the severe contamination risks. After months of failing to classify the recall’s severity, the FDA finally upgraded it to a Class I recall—the most serious category, defined as a situation in which there is a reasonable probability that using or exposure to the recalled product will cause serious health problems or death.

---

The Hidden Recall: Where Neogen Failed to Warn the Public

• Zero Website Warnings: Neogen never displayed a prominent red banner, safety alert, or recall notice on its main commercial website or on the product storefront where customers order supplies. A horse owner or barn manager visiting Neogen’s site would have had no idea a lethal recall was underway.

• Social Media Blackout: Neogen maintained complete radio silence across its public social media accounts. The company made no safety posts, no pinned warnings, and no public outreach on platforms where equestrian communities gather to share news.

• No Direct Consumer Alerts: While Neogen claimed in regulatory correspondence that it was “notifying customers,” that meant quiet, private outreach limited to direct wholesale distributors and large veterinary supply houses. Everyday horse owners—the consumers who actually purchase and use the product—were left completely in the dark.

• Missing from Major Equine Platforms: Across major equestrian associations, breed registries, and horse owner groups, Neogen made zero effort to post warning advisories or issue public safety bulletins to protect the community.

The Quiet Recall Strategy: Wall Street Over Animal Welfare

By burying its voluntary recall notice inside corporate financial channels rather than placing public warnings where horse owners, barn managers, and riders actually look, Neogen Corporation revealed its primary motivation: damage control. The company prioritized containing stock market panic and mitigating legal fallout over preventing further joint destruction in innocent animals.

Neogen’s official disclosure strategy relied strictly on minimal corporate wire distributions:

• The Business Wire Release: Neogen issued a formal corporate announcement titled “Neogen Corporation Announces Voluntary Recall of HYCOAT®” via Business Wire (January 28, 2026). Distributed primarily to financial terminals, stock tickers, and news syndicates, it was structured for equity analysts and fund managers—not the equestrian public.

• The Investor Relations Portal: The notice was simultaneously posted under the “News & Events” tab on Neogen’s official Investor Relations portal. While accessible to shareholders reviewing quarterly filings, no corresponding safety warning or alert banner was placed on Neogen’s main commercial product homepage or veterinary sales storefront.

For months, horse owners whose animals were suffering from sudden, agonizing lameness had no way of knowing that the medical fluid injected into their horse’s joint was manufactured in a filthy, leak-plagued warehouse. Neogen’s decision to restrict its public messaging to financial wire services while maintaining total radio silence across its public storefront and social media channels was not just a communications oversight—it was a spectacular, unpardonable failure of corporate ethics.

---

The Legal Reality: Animals as Mere “Personal Property”

For horse owners seeking justice, the legal system presents severe hurdles. Under American common law, animals are legally classified as personal property.

• Damage Caps: Recovery in property-damage cases is generally capped at the animal’s fair market value, plus direct veterinary expenses.

• Exclusion of Emotional Distress: Most jurisdictions prohibit claims for loss of companionship or emotional distress resulting from the death of an animal.

Creating an official, verifiable paper trail with federal regulators and corporate entities is critical for regulatory enforcement, safety monitoring, and supporting civil litigation. Because Neogen Corporation marketed HYCOAT under a “topical medical device” classification, spontaneous corporate safety reports were not automatically routed to federal drug safety databases. Direct submission to the FDA Center for Veterinary Medicine (CVM) ensures that adverse reactions, product contamination, and equine mortalities are permanently recorded in federal enforcement registries.

---

Class Action Civil Litigation: Holding Neogen Accountable

While horse owners were left searching for answers, affected veterinary practices and animal owners filed federal civil litigation to seek systemic accountability. On April 24, 2026, plaintiffs Tifni Martin and Outlaw Equine Hospital & Rehab Center filed a federal class-action complaint—Martin et al. v. Neogen Corporation et al. (Case No. 5:26-cv-00270-JSM-PRL)—in the U.S. District Court for the Middle District of Florida.

The lawsuit alleges grave claims including product liability, breach of express and implied warranties, gross negligence, and corporate misbranding. By bringing together individual horse owners like Martin with major clinical facilities such as Outlaw Equine Hospital & Rehab Center, the litigation aims to circumvent standard property-limitation defenses and compel full transparency regarding Neogen’s manufacturing oversight failures.

Horse owners and veterinary clinics seeking information regarding representation or participation in the litigation can review the action through lead counsel, Mazzola Law Firm, PLLC, which is handling the case.

---

Why You Must File a Report

• Overcoming Corporate Underreporting: Manufacturers of products marketed as devices or as unapproved formulations are not subject to the same strict 15-day mandatory adverse event reporting timelines that apply to approved animal drugs under 21 CFR § 514.80. Direct reports from veterinarians and horse owners force federal oversight.

• Triggering Federal Enforcement Action: Aggregate adverse event submissions directly to CVM provide the evidentiary threshold required for the FDA to launch field inspections, issue Form FDA 483 observations, seize inventory, and publish formal Warning Letters.

• Building a Legal Paper Trail: Official FDA adverse event filings create unalterable, time-stamped government records that serve as essential primary evidence in civil product liability claims, breach-of-warranty suits, and class-action litigation.

---

Step-by-Step Guide: Filing Form FDA 1932a via Email

The FDA Center for Veterinary Medicine allows clinicians and animal owners to submit voluntary adverse event and product defect reports using Form FDA 1932a (“Veterinary Adverse Experience, Lack of Effectiveness or Product Defect Report”). You do not need to print or mail paper forms; the process can be completed digitally on a computer.

1. Download the Blank Form: Right-click the official Form FDA 1932a Fillable PDF Link and select “Save Link As…” to save the file directly to your desktop or laptop computer. (Note: Do not fill out the form in your web browser, as browser PDF viewers will lose saved data.)

2. Open in Adobe Acrobat: Open the saved PDF file using standard desktop software (Adobe Acrobat Reader, Preview, or similar PDF application).

3. Complete Required Fields:

   • Reporter & Owner Information: Fill in clinician/owner contact details, clinic name, physical address, and telephone number. (The FDA keeps personally identifiable information strictly confidential under federal privacy law.)

   • Animal Patient Details: Enter species (Horse), age, weight, breed, and current health status prior to administration.

   • Suspected Product Identifiers: Record the product name (Neogen Vet HYCOAT), manufacturer (Neogen Corp / Sciarra Aeromed), dosage form, route of administration, exact Lot Number, and Expiration Date as listed on the vial or box.

   • Detailed Event Narrative: Describe the clinical timeline, including date of administration, initial onset of symptoms (e.g., rapid joint effusion, severe heat, non-weight-bearing lameness), diagnostic findings, joint fluid culture results (Purpureocillium lilacinum), treatments attempted, and outcome (e.g., chronic impairment or euthanasia).

4. Attach Supporting Evidence: Save copies of veterinary medical records, joint aspirate lab reports, diagnostic radiographs, and photographs of product vials or affected joints.

5. Submit via Email: Save the completed PDF on your computer and attach it along with your supporting documents in an email sent directly to the FDA CVM inbox:

   • FDA Submission Email: CVM1932a@fda.hhs.gov

   • Subject Line Format: Adverse Event Report - Neogen Vet HYCOAT - [Your State]

6. Confirmation & Follow-Up: You will receive an automated email confirmation from the FDA containing a unique reference tracking number. Keep this confirmation email for your records.

---

Evidentiary Checklist for Affected Horse Owners and Clinicians

To protect your legal rights and provide FDA investigators with actionable evidence, gather and organize the following materials into a dedicated binder or secure digital folder:

• Complete Veterinary Medical Records: Full clinical SOAP notes, physical examination records, joint temperature logs, and lameness evaluation scores before and after administration.

• Diagnostic Laboratory & Culture Reports: Official laboratory reports documenting joint fluid cytology, cell counts, and microbiological culture results confirming fungal growth (Purpureocillium lilacinum or other mold species).

• Diagnostic Imaging Files: Original DICOM files or exported JPEGs of joint radiographs, ultrasound, or MRI scans demonstrating articular cartilage erosion, soft-tissue swelling, or joint-space narrowing.

• Physical Product Evidence & Retention:

  • Retain all used, partially filled, or unopened HYCOAT glass vials.

  • Store physical vials in clean, sealed Ziploc bags at room temperature to preserve potential residue for independent chemical and microbiological testing.

  • Retain the original cardboard packaging, outer cartons, and inserts that show printed Lot Numbers and Expiration Dates.

• Itemized Financial Ledger:

  • Invoices for initial product purchase and administration fees.

  • Itemized veterinary bills for joint lavages, diagnostic imaging, joint fluid culturing, systemic/intra-articular medications, and intensive hospital care.

  • Receipts for therapeutic shoeing, supportive care, and treatments for opposing-limb laminitis.

  • Documentation of euthanasia, necropsy fees, and cremation or burial expenses.

• Horse Identification & Valuation Documents: Registration papers (e.g., AQHA, Jockey Club, USEF), proof of purchase price, professional appraisal records, competition records, and breeding revenue documentation to substantiate fair market valuation.

---

Reporting Directly to Neogen Corporation

In addition to notifying federal regulators, submitting a formal written adverse event report directly to Neogen Corporation ensures the company cannot claim ignorance regarding specific animal injuries or lot-specific contamination.

• Neogen Customer Service & Safety Line: Call (800) 234-5333 or (517) 372-9200 to log an official product complaint.

• Written/Email Incident Notice: Request a formal case/claim number and send written notice outlining the clinical event, lot number, and financial impact to Neogen’s corporate headquarters:

  • Mailing Address: Neogen Corporation, Attn: Veterinary Safety & Quality Assurance, 620 Lesher Place, Lansing, MI 48912

  • Corporate Website Portal: Neogen Corporation Contact Gateway

• Preserve Corporate Correspondence: Keep detailed written notes of all phone conversations with Neogen representatives, including the date, time, the representative’s name, and any claim identification numbers provided.

Below is a comprehensive directory of official regulatory portals, federal warning letters, trade journalism, medical literature, legal precedents, and corporate contact details that support this investigative report.

---

Direct Safety Reporting, Portals, and Official FDA Guidelines

• FDA CVM Primary Safety Portal: FDA Center for Veterinary Medicine Report a Problem Hub

  Main directory for reporting animal drugs, devices, and product defects.

• FDA Official Reporting Instructions: How to Report Animal Drug and Device Side Effects and Product Problems

  The FDA’s comprehensive guide for animal owners and veterinarians detailing preferred report contents (pre-existing health, veterinary exams, bloodwork/x-ray findings, feed/treats, and physical vial retention).

• Voluntary Adverse Event Form (FDA 1932a): Download Fillable Form FDA 1932a (PDF)

  Fillable PDF form for reporting adverse experiences, lack of effectiveness, packaging misbranding, or product defects. Submit as an email attachment to CVM1932a@fda.hhs.gov.

• FDA CVM Adverse Event Database: Adverse Event Reports for Animal Drugs and Devices (openFDA)

  Publicly searchable database of post-market adverse experience reports.

• FDA CVM Contact Information:

  • Email: AskCVM@fda.hhs.gov

  • Toll-Free Phone: 1-888-FDA-VETS (1-888-332-8387)

  • Mailing Address: Food and Drug Administration, Center for Veterinary Medicine, 5001 Campus Dr., Rockville, MD 20852

Official Regulatory Enforcement Actions & Warnings

• FDA CVM Update Summary (Sept 29, 2026): FDA Issues Warning Letters Following Fungal Contamination in a Veterinary Product Linked to Serious Infections in Nearly 100 Horses

  Official press release detailing the investigation, fungal pathogens, 100 infections, and 20+ euthanasias.

• FDA Warning Letter — Neogen Corporation: FDA Warning Letter to Neogen Corporation (Sept 23, 2026)

  Formal regulatory citations for product misbranding, adulteration, and packaging misrepresentation.

• FDA Warning Letter — Sciarra Aeromed, Inc.: FDA Warning Letter to Sciarra Aeromed, Inc. (Sept 23, 2026)

  Formal citations detailing insanitary cleanroom manufacturing and GMP violations.

• FDA FOIA Electronic Reading Room: FDA ORA FOIA Electronic Reading Room

  Public repository for requested Form FDA 483 inspectional observations.

Trade Media & Investigative News Reporting

• dvm360 News Analysis: Fungus-Contaminated Wound Product Linked to Infections in Nearly 100 Horses

  Veterinary trade journal breakdown detailing Form FDA 483 inspection findings at the Sciarra Aeromed facility.

• EquiManagement Regulatory Alert: FDA Issues Warning Letters Following Fungal Contamination in HYCOAT

  Equine veterinary industry coverage of off-label intra-articular risks.

• American Animal Hospital Association (AAHA): Recall Alert: Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution

  Initial January 28, 2026 recall notification listing affected 2-mL and 10-mL vial lot numbers.

• National Animal Supplement Council (NASC): NASC Recall Portal: Neogen Vet HYCOAT

  Product recall parameters and lot identification guide.

• Seeking Alpha Financial Analysis: Neogen Drops After FDA Warning on HYCOAT

  Financial reporting on stock drops and corporate disclosure timelines.

• Legal Newsline Coverage: Class Action Targets Contaminated Joint Injection for Horses

  Reporting on civil product liability lawsuits filed by affected horse owners.

Medical Literature & Pathology References

• American College of Veterinary Surgeons (ACVS): Septic Arthritis in Horses

  Clinical summary of synovial membrane inflammation and articular cartilage degradation.

• National Institutes of Health (NIH / PMC): Purpureocillium lilacinum Infections and Antifungal Resistance

  Peer-reviewed pathology paper detailing the drug-resistant nature of Purpureocillium mold.

• Purdue University College of Veterinary Medicine: Equine Septic Arthritis Pathology and Prognosis

  Veterinary diagnostic laboratory notes on cartilage destruction, lameness, and survival rates.

• The Equine Documentalist: Supporting Limb Laminitis in Equine Patients

  Clinical breakdown of mechanical weight-shifting and secondary hoof vascular collapse.

Legal Precedents & Legal Classification Sources

• Animal Legal & Historical Center: Determining Value of Companion Animals in Wrongful Harm or Death Claims

  Survey of U.S. court decisions treating companion animals and livestock as personal property.

• Florida District Court of Appeal Precedent: Bennett v. Bennett, 655 So. 2d 109 (Fla. Dist. Ct. App. 1995)

  Landmark case confirming animals are personal property under common law.

• CSG Law Firm Legal Overview: The Value of a Pet When Injured or Killed: An Overview

  Legal summary on how courts cap damages at fair market value and exclude emotional distress.

Manufacturer Contact Information

• Company Name: Neogen Corporation

• Corporate Headquarters: 620 Lesher Place, Lansing, MI 48912

• Toll-Free Phone: 800-234-5333 or 517-372-9200

• Customer Care / Product Safety Email: inform@neogen.com

• Official Website: www.neogen.com